Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital

University of Colorado Denver (CU Denver)

Status and phase: Completed; Phase 4

Conditions: Diabetes

Treatments: Drug: Glargine insulin

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01203774

10-0788

Details and patient eligibility

About

In this study the investigators would like to test the hypothesis that in diabetic patients discharged from the hospital, SoloSTAR Glargine insulin will be superior to syringe-injected Glargine in terms of diabetes control, compliance, and patient satisfaction and preference. The investigators will test this hypothesis in a randomized, crossover trial.

Enrollment: 43 patients

Sex: All

Ages: 22 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients with type 1 and 2 diabetes discharged from the hospital with recommendations to take Glargine

Exclusion criteria

• Patients unwilling to participate and patients incapable of complying with the study regimen, such as patients with alcohol and drug addiction problems and patients with severe mental illness

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

43 participants in 2 patient groups

Pen-administered vs syringe-admnistered Glargine

Active Comparator group

Description:

SoloSTAR pen-administered Glargine insulin then syringe-administered Glargine insulin

Treatment:

Drug: Glargine insulin

Syringe-administered vs pen-administered Glargine

Active Comparator group

Description:

Syringe-administered Glargine insulin and then pen-administered Glargine insulin

Treatment:

Drug: Glargine insulin